Boehringer Ingelheim Faces Setback, Judge Rules Against Pharma Giant In Medicare Negotiation Battle
Judge dismisses Boehringer Ingelheim's challenge to Medicare drug price negotiation program.
A federal judge has rejected Boehringer Ingelheim's
challenge to the new Medicare drug price negotiation program, marking another
legal defeat for the pharmaceutical industry. The company contended before the
U.S. District Court of Connecticut that the drug pricing law was
unconstitutional based on four constitutional provisions and that Medicare
officials had breached procedural laws.
Judge Michael Shea dismissed Boehringer Ingelheim's
arguments on all counts in a decision released late Wednesday. Boehringer
Ingelheim has yet to comment on the ruling. The company's diabetes drug,
Jardiance, was among the first medications chosen for the negotiation program.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Ab Science rivede i tempi dei trial dopo tre ispezioni GCP
Novo Nordisk Firma un Accordo da $2.6B con Hengrui per GLP-1 Orale
Discussion